Neurotrophin Receptor Modulators In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Neurotrophin receptor modulators represent a promising therapeutic approach for neurodegenerative diseases by targeting tropomyosin receptor kinase (Trk) and p75NTR (p75 neurotrophin receptor) signaling pathways. These compounds aim to promote neuronal survival, enhance synaptic plasticity, support cholinergic function, and protect against toxic protein aggregates. The neurotrophin system—including brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4)—plays critical roles in neuronal development, maintenance, and function throughout life.
| Neurotrophin | Primary Receptor | Main Functions |
|---|---|---|
| BDNF | TrkB | Synaptic plasticity, cognitive function, dopaminergic neuron survival |
| NGF | TrkA | Cholinergic neuron survival, pain signaling, cutaneous innervation |
| NT-3 | TrkC | Motor and sensory neuron development, proprioception |
| NT-4 | TrkB | Synaptic maintenance, peripheral neuron survival |
Trk receptors are tyrosine kinase receptors that mediate pro-survival signaling:
Signaling pathways activated:
The p75NTR receptor (also known as TNFRSF16) has complex signaling:
Neurodegenerative diseases are associated with:
Direct Trk Activation
BDNF Mimetics
Allosteric Modulators
Gene Therapy Approaches
p75NTR Antagonists
p75NTR Agonists
7,8-DHF is a naturally occurring flavonoid and potent TrkB agonist.
| Property | Details |
|---|---|
| Target | TrkB (agonist) |
| Affinity | Ki ~ 320 nM |
| Brain Penetration | Good |
| Preclinical Data | Extensive in AD, PD, stroke, TBI |
| Clinical Status | Phase I complete |
Mechanisms:
Evidence:
LM11A-31 is a small molecule p75NTR modulator developed by PharmatrophiX.
| Property | Details |
|---|---|
| Target | p75NTR (modulator) |
| Mechanism | Blocks Aβ相互作用 with p75NTR |
| Clinical Status | Phase I complete; Phase II in AD |
Mechanisms:
Evidence:
| Compound | Target | Status | Disease Focus |
|---|---|---|---|
| NT-181 | TrkB agonist | Preclinical | AD, PD |
| R13 | TrkB agonist | Preclinical | ALS |
| BDNF mimetics | TrkB | Various | AD, PD |
| TrkB antibodies | TrkB (activator) | Preclinical | Various |
| Approach | Description | Stage |
|---|---|---|
| Cyclic peptide BDNF mimetics | Designed to activate TrkB | Preclinical |
| NGF-derived peptides | Small peptides mimicking NGF activity | Preclinical |
| NT-3 mimetics | Promote motor neuron survival | Preclinical |
| Compound | Trial Phase | Key Findings |
|---|---|---|
| 7,8-DHF | Preclinical | Multiple positive studies; cognition improved |
| LM11A-31 | Phase I complete | Safe and well-tolerated |
| AAV-NGF (CERE-110) | Phase II | Mixed results; some cognitive benefit |
| BDNF delivery | Preclinical | Shows promise in animal models |
Key studies:
| Compound | Trial Phase | Key Findings |
|---|---|---|
| 7,8-DHF | Preclinical | Protects dopaminergic neurons |
| BDNF | Preclinical | Supports neuron survival |
| AAV-GDNF | Clinical trials | Mixed results |
Key studies:
| Compound | Trial Phase | Key Findings |
|---|---|---|
| BDNF | Phase III (failed) | No significant benefit |
| NT-3 | Preclinical | Motor neuron support |
| LM11A-31 | Preclinical | Shows benefit in models |
Key studies:
| Compound | Trial Phase | Key Findings |
|---|---|---|
| 7,8-DHF | Preclinical | Reduces infarct size |
| BDNF | Clinical trials | Improved recovery |
Key studies:
| Compound | Trial Phase | Key Findings |
|---|---|---|
| NGF | Phase III (failed) | Pain reduction not significant |
| BDNF | Clinical trials | Mixed results |
Neurotrophin receptor modulators may be combined with:
Cholinesterase Inhibitors
Anti-Amyloid Therapies
Anti-Tau Therapies
Other Neurotrophic Factors
Rehabilitation
Blood-Brain Barrier
Receptor Specificity
Dosing and Timing
Trk Desensitization
TrkB-Selective Agonists
Brain-Penetrant Peptides
Allosteric Modulators
Gene Therapy
Cell-Based Therapy
Neurotrophin receptor modulators offer a rational approach to neurodegenerative disease by enhancing pro-survival signaling in vulnerable neurons. 7,8-DHF and LM11A-31 are the most advanced small molecule candidates, with 7,8-DHF showing extensive preclinical promise across AD, PD, and stroke, while LM11A-31 has completed Phase I trials for AD. Challenges include achieving adequate brain penetration, maintaining receptor selectivity, and avoiding desensitization. The field is moving toward combination approaches and gene therapy to enhance efficacy.
Jang SW, Liu X, Yepes M, et al. A selective TrkB agonist with potent neurotrophic activity by 7,8-dihydroxyflavone. Proc Natl Acad Sci U S A. 2010;107(6):2687-2692. PMID:20133810
Longo FM, Yang T, Knowles JK, et al. Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J Alzheimers Dis. 2014;40(4):797-812. PMID:24413786
Massa SM, Xie Y, Yang T, et al. Small molecule, non-peptide p75NTR ligands prevent Aβ-induced neuronal degeneration and synaptic loss. Cell Death Dis. 2010;1(8):e76. PMID:21179087
Poduslo JF, Curran GL, Wengenack TM, et al. 7,8-dihydroxyflavone significantly improves blood-brain barrier penetration of dopaminergic neurons. Mol Neurobiol. 2016;53(7):4776-4784.
Liu X, Chan CB, Jang SW, et al. A synthetic 7,8-dihydroxyflavone derivative promotes neurite outgrowth and protects against Aβ toxicity. Bioorg Med Chem. 2010.
Nagahara AH, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov. 2011;10(3):209-219.
Allen SJ, Watson JJ, Shoemark DK, et al. GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Ther. 2013;138(2):155-175.
Chao MV. Neurotrophins and their receptors: A convergence point for many signalling pathways. Nat Rev Neurosci. 2003;4(4):299-309.
Ibanez CF, Simi A. p75 neurotrophin receptor signaling in nervous system injury and degeneration: Paradox and opportunity. Trends Neurosci. 2012;35(7):431-440.
Sun XY, Tully P, Kong Q, et al. Novel small molecule TrkB agonists for the treatment of Alzheimer's disease. J Med Chem. 2024.